Aims and objectives: To summarise the current state of knowledge of symptom clusters research from studies that included, as part of their sample, patients who were receiving primary or adjuvant chemotherapy.
more symptoms that are related to each other and occur together.
Symptom clusters are composed of stable groups of symptoms, are relatively independent of other clusters and may reveal specific underlying concepts of symptoms. Relationships among symptoms within a cluster should be stronger than relationships among symptoms across different clusters. Symptoms in a cluster may or may not share the same etiology" [p. 278] .
More recently, an expert panel called for a comprehensive evaluation of symptom clusters research (Miaskowski et al., 2017) . Given that patients with chronic conditions rarely present with a single symptom, the concept of a symptom cluster has important implications for clinical practice. However, as noted in the report from the expert panel, numerous questions remain unanswered in the area of symptom cluster research.
As most of the research on symptom clusters was done in oncology patients, one way to evaluate the "state of the science" in symptom clusters research in oncology patients is to conduct a review of the literature. A synthesis of the current state of knowledge that is organised around some of the key questions in symptom clusters research will provide a foundation for future studies in this important area of scientific inquiry.
| Previous reviews of symptom clusters research in oncology
Since the concept of a symptom cluster was first introduced into the oncology literature in 2001, only four comprehensive reviews were identified that provide insights into this important concept in symptom management research (Dodd, Miaskowski, & Lee, 2004; Fan, Filipczak, & Chow, 2007; Nguyen et al., 2011; Xiao, 2010) . While several additional reviews of symptom clusters research were published on a variety of topics Dong, Butow, Costa, Lovell, & Agar, 2014; Thavarajah et al., 2012) , we critiqued the four reviews that included studies whose samples, at least in part, were receiving primary or adjuvant chemotherapy (CTX).
In the first review published by Dodd et al. (2004) , only three studies were identified that evaluated symptom clusters in oncology patients. All three of these studies evaluated the association between a prespecified symptom cluster and a patient outcome (e.g., functional status). In two of these studies that evaluated patients with heterogeneous cancer diagnoses (Dodd et al., 2001; Given, Given, Azzouz, & Stommel, 2001) , pain, fatigue, and sleep disturbance was the prespecified symptom cluster. In the third study of patients with breast cancer (Gaston-Johansson, Fall-Dickson, Bakos, & Kennedy, 1999) , the prespecified symptom cluster was pain, fatigue and depression. All of the symptoms in these studies were selected because previous research had demonstrated that they were moderately to highly correlated with each other. Findings from this review suggest that none of the studies identified a symptom cluster "de novo" using analytic techniques like cluster analysis or factor analysis (Miaskowski, Aouizerat, Dodd, & Cooper, 2007) . In addition, no studies were found that evaluated the occurrence of symptom clusters in children or adolescents, or by stage of cancer, or across the continuum of cancer care. The authors concluded their review by enumerating key areas for future research on symptom clusters (e.g., whether the occurrence of a symptom cluster influences patient outcomes).
The second review of symptom clusters research spanned the years 1997 to 2006 (Fan et al., 2007) . The purposes of this review were to identify the occurrence of common symptom clusters in oncology patients and to evaluate for predictors of symptom clusters. Of the twelve studies identified, seven evaluated patients with heterogeneous cancer diagnoses (Chen & Tseng, 2006; Cleeland et al., 2000; Ivanova et al., 2005; Okuyama et al., 2003; Walsh & Rybicki, 2006; Wang et al., 2006; Wang et al., 2004 ) and five evaluated patients with a single cancer diagnosis (i.e., three evaluated symptom clusters in breast cancer patients (Bender, Ergyn, Rosenzweig, Cohen, & Sereika, 2005; Glaus et al., 2006; Ridner, 2005) ; two evaluated symptom clusters in lung cancer patients (Gift, Jablonski, Stommel, & Given, 2004; Sarna & Brecht, 1997) ). Across these studies, sample sizes ranged from 60 (Sarna & Brecht, 1997 )-922 (Walsh & Rybicki, 2006) .
For the seven studies that evaluated for symptom clusters in patients with a variety of cancer diagnoses (Chen & Tseng, 2006; Cleeland et al., 2000; Ivanova et al., 2005; Okuyama et al., 2003; Walsh & Rybicki, 2006; Wang et al., 2006; Wang et al., 2004) , several observations are worth noting. First, the MD Anderson Symptom Inventory (MDASI) (Cleeland et al., 2000) was used to assess symptoms in six of the seven studies. Rather than evaluate a prespecified symptom cluster, all seven studies created symptom clusters "de novo" . Factor analysis was used in six of the seven studies to identify the symptom clusters (Chen & Tseng, 2006; Cleeland et al., 2000; Ivanova et al., 2005; Okuyama et al., 2003; Wang et al., 2006; Wang et al., 2004) . The two most common symptom clusters were a "general" symptom cluster and a "gastrointestinal" (GI) symptom cluster.
As part of this second review (Fan et al., 2007) , three studies evaluated symptom clusters in patients with breast cancer (Bender et al., 2005; Glaus et al., 2006; Ridner, 2005) and two included patients with lung cancer (Gift et al., 2004; Sarna & Brecht, 1997) .
What does this paper contribute to the wider global clinical community?
• Given the international interest in symptom clusters research in oncology patients, the findings from this review clearly identify gaps in our knowledge and directions for future research.
• Across the studies in this review, a gastrointestinal and a psychological symptom cluster were identified consistently and warrant evaluation in oncology patients.
• The information provided in this review can be used by nurse scientists to design studies that evaluate symptom clusters in oncology patients. WARD SULLIVAN ET AL. Across these five studies, with homogenous samples in terms of their cancer diagnoses, no consistent symptom assessment tool or statistical approach was used to identify the symptom clusters. In addition, the symptom clusters identified within each cancer diagnosis were inconsistent. Based on the findings from their review (Fan et al., 2007) , Fan and colleagues concluded that it may be too early to confirm or deny the existence of common symptom clusters in oncology patients. In addition, they suggested that a consensus needed to be reached on the definition of a symptom cluster, as well as on the symptoms that should be assessed and the statistical methods that should be used to identify symptom clusters.
An updated review of the literature on symptom clusters spanned the years 1999 to 2010 (Xiao, 2010) . A total of 61 studies were evaluated of which 22 used a longitudinal design. The sample sizes ranged from 15-2,161. The majority of these studies evaluated heterogeneous samples in terms of cancer diagnoses. A wide variety of symptom assessment tools were used across the 61 studies. The studies were divided into two groups: the "most common symptoms" approach (i.e., researchers evaluated the most common symptoms experienced by oncology patients and used these symptoms to identify symptom clusters) and the "all-possible symptoms" approach (i.e., a more commonly used approach, where the researchers evaluated a large number of symptoms that oncology patients may experience to identify symptom clusters rather than using only the most common symptoms). In the "most common symptoms" approach, which included 20 studies, 80.0% of the studies used a combination of correlation and/or regression analyses to identify symptom clusters. In the "all-possible symptoms" approach, factor analysis was used in 27.0% of the studies and cluster analyses in 21.0% of the studies to create the symptom clusters.
Across the 61 studies, the types of symptom clusters identified were highly variable. However, the most common symptom clusters were as follows: pain and fatigue; pain and sleep disturbance; depression, fatigue and pain; and a cluster labelled GI. At the end of their review (Xiao, 2010) , Xiao recommended that additional research was needed to operationally define a symptom cluster; develop theoretical frameworks for the use of symptom clusters in oncology; determine the best methods of analysis; diversify the populations of patients evaluated; and explore how symptom clusters influence patient outcomes.
In the most recent review of symptom clusters research , the five studies that were evaluated included only patients with breast cancer (Bender et al., 2005; Fu et al., 2009; Glaus et al., 2006; Kim, Barsevick, Tulman, & McDermott, 2008; Ridner, 2005) . Across these studies, the sample sizes ranged from 64 (Ridner, 2005 )-373 (Glaus et al., 2006 . To identify the symptom clusters de novo, two studies used factor analysis (Fu et al., 2009; Kim et al., 2008) , two used cluster analysis (Bender et al., 2005; Glaus et al., 2006) and one used analysis of variance (ANOVA) (Ridner, 2005) . One of the five studies assessed symptom clusters in women experiencing menopausal symptoms (Glaus et al., 2006) and another evaluated women with lymphoedema (Ridner, 2005) . The instruments used to evaluate for symptom clusters, as well as the symptoms identified, varied across these five studies. No common symptom cluster was found across these five studies. Nguyen et al. (2011) concluded that even though symptom clusters were evaluated in patients with a single cancer diagnosis, several issues warrant consideration. For example, among the five studies (Bender et al., 2005; Fu et al., 2009; Glaus et al., 2006; Kim et al., 2008; Ridner, 2005) , three different methods of analysis were used; symptom data were measured at varying time points; and only one study used a longitudinal design. Of note, while several symptoms were found within a number of symptom clusters, none of these symptoms were included in the same symptom cluster. In addition, type of treatment, the symptom dimension used to create the symptom clusters and temporal measurements of the symptom clusters were not described in this literature review of patients with breast cancer.
| Issues in symptom clusters research
While these four reviews provide an excellent overview of symptom clusters research in oncology patients, none of them provided a detailed evaluation of the major issues in this field of inquiry. In fact, based on the findings from these four reviews (Dodd et al., 2004; Fan et al., 2007; Nguyen et al., 2011; Xiao, 2010) , numerous unanswered questions remain about this emerging area of symptom management research. For example, which analytical approaches (e.g., cluster analysis, factor analysis) and which dimensions of the symptom experience (e.g., occurrence, severity, distress) should be used to identify symptom clusters. An equally important consideration that warrants additional evaluation includes whether or not the number of symptoms evaluated influences the number of symptom clusters identified and the specific symptoms within a cluster. In addition, questions regarding whether or not the number and types of symptom clusters vary based on cancer diagnoses (i.e., whether the number and types of symptom clusters vary based on whether the sample includes patients who are heterogeneous or homogeneous with respect to their cancer diagnosis), cancer treatments (i.e., whether the number and types of symptom clusters vary based on whether the sample includes patient who are heterogeneous or homogeneous with respect to their cancer treatment) and timing of the symptom assessments warrant consideration in future reviews.
Given the numerous questions and issues that warrant investigation in symptom clusters research, as well as the heterogeneous nature of the four reviews conducted to date (Dodd et al., 2004; Fan et al., 2007; Nguyen et al., 2011; Xiao, 2010) , this review of symptom clusters research focused on studies that included, as part of their sample, patients who were receiving primary or adjuvant cancer CTX.
This review was designed with the following objectives: to summarise the current state of knowledge of symptom clusters' research from studies that included, as part of their sample, patients who received primary or adjuvant CTX; to identify the most common symptom assessment instruments used; to determine the most common statistical approaches used to create the clusters; to identify the symptom dimensions used to create the symptom clusters; to determine the average number of symptom clusters identified; to evaluate the specific symptoms identified within each cluster; and to determine whether symptom clusters changed over time.
| ME TH ODS
A comprehensive literature search was conducted for the years 2000 to 2016. The following databases were accessed for this review: PubMed, the Cochrane Library, Cumulative Index to Nursing and Allied Health Literature (CINAHL), Google Scholar, and PsycINFO. The key words used were as follows: symptom clusters AND cancer not syndrome; symptom cluster AND cancer; symptoms, AND clusters, AND cancer; and symptom clusters, AND CTX, AND patients; and neoplasms, symptom clusters, AND cancer patients, AND CTX, AND treatment. Studies were included if they met all of the following criteria: (1) the entire sample had a cancer diagnosis;
(2) the sample included, at least in part, patients who were receiving primary (i.e., initial treatment) or adjuvant (i.e., CTX following primary cancer treatment) CTX; (3) patients were ≥18 years of age; and (4) identified a symptom cluster in the analysis. Studies were excluded if patients were in the advanced stage of their cancer (i.e., receiving palliative or hospice care); if patients had completed cancer treatment and were described as cancer survivors; or if the study evaluated a prespecified symptom cluster.
As shown in Figure 1 , in the final search with a reference librarian, 55 papers were identified using the PubMed database; six from the Cochrane Library; 23 from CINAHL; six from Google Scholar; and 186 from PsycINFO. The majority of these papers were eliminated because they did not directly relate to symptom clusters in cancer patients. Duplicate articles found across the databases were eliminated. Using our prespecified inclusion and exclusion criteria, 13 studies were selected from the PubMed, four from the Google Scholar, and two from the PsycINFO searches. A total of nineteen studies met the criteria for inclusion in this literature review (Brown, Cooley, Chernecky, & Sarna, 2011; Chen & Lin, 2007; Chen & Tseng, 2006; Gift et al., 2004; Gift, Stommel, Jablonski, & Given, 2003; Huang et al., 2016; Hwang, Cho, & Yoo, 2016; Karabulut, Erci, Ozer, & Ozdemir, 2010; Kim et al., 2008; Molassiotis, Wengstrom, & Kearney, 2010; Phligbua et al., 2013; Ryu et al., 2010; Skerman, Yates, & Battistutta, 2012a; Suwisith et al., 2008; Thomas et al., 2014; Records identified through database searching n = 55 from PubMed n = 6 from Cochrane Library n = 23 from CINAHL n = 6 from Google Scholar n = 186 from PsycINFO Additional records identified through other sources (n = 0)
Records after duplicates removed (n = 149)
Records screened (n = 149)
Records excluded that did not meet inclusion criteria (n = 130)
Full-text articles assessed for eligibility (n = 19)
Full-text articles excluded (n = 0)
Studies included in qualitative synthesis (n = 0)
Studies included in quantitative synthesis (n = 19) Fu, 2014; Wang, Tsai, Chen, Lin, & Lin, 2008; Yamagishi, Morita, Miyashita, & Kimura, 2009; Yates et al., 2015) .
To be able to answer the specific aims of this review, findings from these nineteen studies are summarised in Tables 1 through 4. The tables are grouped by study design (i.e., cross-sectional or longitudinal) and by whether or not the sample included only a single cancer diagnosis (i.e., homogeneous sample) or multiple cancer diagnoses (i.e., heterogeneous sample). The studies are summarised in four tables (i.e., cross-sectional heterogeneous samples (Table 1) ; cross-sectional homogeneous samples (Table 2) ; longitudinal heterogeneous samples (Table 3) ; and longitudinal homogeneous samples (Table 4) ). This organisational approach was chosen to be able to evaluate whether symptom clusters were different when samples included patients with only a single cancer diagnosis or heterogeneous cancer diagnoses and whether or not the symptom clusters changed over time.
Each of the studies was reviewed by the first and last author to answer the prespecified objectives of this review that were created after reviewing three papers that identified unanswered questions in symptom clusters research (Molassiotis et al., 2010; Skerman, Yates, & Battistutta, 2009; Skerman et al., 2012a) . If discrepancies occurred during these reviews, they were discussed and a consensus was reached.
From a methodological perspective, the following criteria were evaluated: study design, sample size, and patient characteristics. To describe the nature of the symptom clusters, the following criteria were evaluated: timing of the symptom assessment; symptom assessment instrument used; number of symptoms included in the instrument; statistical analysis method used to create the symptom clusters; symptom dimension used to create the symptom clusters; number of symptom clusters identified; specific symptoms within each cluster; and changes in symptom clusters over time. The final objective of this review was to evaluate the strengths and limitations of each of the studies.
3 | RESULTS 3.1 | Cross-sectional studies with heterogeneous samples As shown in Table 1 , five cross-sectional studies evaluated for symptom clusters in samples of patients with heterogeneous cancer diagnoses (Chen & Lin, 2007; Chen & Tseng, 2006; Karabulut et al., 2010; Yamagishi et al., 2009; Yates et al., 2015) . The sample sizes ranged from 151 (Chen & Tseng, 2006 )-462 (Yamagishi et al., 2009 .
Across these studies, the majority of the patients were female (i.e., weighted grand mean of 51.9%). Ages ranged from 18-97 with a weighted grand mean of 60.3 years. Of the three studies that included setting, two recruited patients primarily from an outpatient setting (Chen & Lin, 2007; Yates et al., 2015) . Across these five studies, CTX was the most prevalent treatment modality used.
Three of the five studies used the MDASI to assess symptoms (Chen & Lin, 2007; Chen & Tseng, 2006; Karabulut et al., 2010) . Of these three studies, one used a modified version of MDASI (Chen & Lin, 2007) . Only one of these three studies used the Depression Subscale of Hospital Anxiety and Depression Scale (HADS-D) in conjunction with the MDASI (Chen & Tseng, 2006) . The fourth study developed a population specific instrument using eight items from the MDASI and several additional items (Yamagishi et al., 2009 ). The fifth study used the Memorial Symptom Assessment Scale (MSAS) to assess the symptoms (Yates et al., 2015) . The statistical methods used to identify the symptom clusters varied across the five studies. Two studies used cluster analysis (Karabulut et al., 2010; Yamagishi et al., 2009) ; two studies used exploratory factor analysis (EFA) (Chen & Tseng, 2006; Yates et al., 2015) ; and the other study used confirmatory factor analysis (CFA) (Chen & Lin, 2007) .
In two studies (Chen & Lin, 2007; Chen & Tseng, 2006) , severity was the dimension used to create the symptom clusters. One study did not specify the symptom dimension used (Yamagishi et al., 2009) , and the fourth study used occurrence as the dimension to create the symptom clusters (Yates et al., 2015) . The fifth study used severity and interference to identify the clusters (Karabulut et al., 2010 ).
Three of the five studies identified three symptom clusters (Chen & Lin, 2007; Chen & Tseng, 2006; Karabulut et al., 2010) . One study identified four symptom clusters (Yamagishi et al., 2009 ). In the study that evaluated for differences in older versus younger oncology patients (Yates et al., 2015) , seven symptom clusters were identified for both age groups. However, between the two age groups, the symptom clusters were not identical.
In terms of the types of symptom clusters, in the two studies conducted by Chen and Lin (2007) and Chen and Tseng (2006) , the same symptom clusters and the same symptoms within each cluster were identified. In the study by Karabulut et al. (2010) , the clusters were identified only as "cluster 1, cluster 2 and cluster 3." In the study that identified four symptom clusters (Yamagishi et al., 2009) , the clusters were named as follows: "cluster 1, cluster 2, cluster 3 and cluster 4." In the study that evaluated for age differences in symptom clusters (Yates et al., 2015) , four of the seven symptom clusters (i.e., mood-cognitive, malaise, genitourinary (GU), CTX toxicity) were given the same names and the symptoms within each cluster were relatively similar. The three unique symptom clusters in the younger age group (i.e., <60 years of age) were as follows: treatment-related, treatment-related GI and hormonal. The three unique symptom clusters in the older age group (i.e., ≥60 years of age) were as follows: aerodigestive, nutrition and age-related. Across the five cross-sectional studies with heterogeneous samples, the most common symptom clusters were as follows: the GI symptom cluster and the mood or emotional symptom cluster.
3.2 | Cross-sectional studies with homogeneous samples As shown in diagnoses (Gift et al., 2004; Hwang et al., 2016; Ryu et al., 2010; Suwisith et al., 2008; Wang & Fu, 2014; Wang et al., 2008) . Three studies evaluated patients with lung cancer (Gift et al., 2004; Wang & Fu, 2014; Wang et al., 2008) , one study evaluated patients with breast cancer (Suwisith et al., 2008) , another study evaluated patients with ovarian cancer (Hwang et al., 2016) , and the sixth study evaluated patients with hepatocellular carcinoma (Ryu et al., 2010) . The sample sizes ranged from 108 (Wang et al., 2008 )-320 (Suwisith et al., 2008) , and women accounted for more than half of the participants (i.e., weighted grand mean of 60.4%). For the five studies that reported an age range (Gift et al., 2004; Hwang et al., 2016; Suwisith et al., 2008; Wang & Fu, 2014; Wang et al., 2008) , ages ranged from 18-90 years with a weighted grand mean of 56.8 years. The majority of the patients were recruited from outpatient settings. Of the five studies that specified various treatment modalities (Gift et al., 2004; Hwang et al., 2016; Suwisith et al., 2008; Wang & Fu, 2014; Wang et al., 2008) , CTX was the most common treatment.
In the four studies that reported the timing of the symptom assessments (Gift et al., 2004; Hwang et al., 2016; Ryu et al., 2010; Suwisith et al., 2008) , patients reported symptoms from the time period following surgery (Hwang et al., 2016) up to ≥5 years after their cancer diagnoses (Ryu et al., 2010) . While one study used five different instruments to assess symptoms (Ryu et al., 2010) , the other five studies (Gift et al., 2004; Hwang et al., 2016; Suwisith et al., 2008; Wang & Fu, 2014; Wang et al., 2008) used from onefour instruments. All six studies used some type of factor analysis to identify the symptom clusters. In addition, one study used CFA and hierarchical cluster analysis (HCA) in conjunction with EFA (Wang et al., 2008) ; one study used ANOVA and the Scheffe test in conjunction with EFA (Hwang et al., 2016) ; and another study used multiple regression in conjunction with EFA (Suwisith et al., 2008) .
Across all six studies (Gift et al., 2004; Hwang et al., 2016; Ryu et al., 2010; Suwisith et al., 2008; Wang & Fu, 2014; Wang et al., 2008) , symptom severity was the dimension used to create the symptom clusters. However, one study used symptom occurrence in addition to severity to create the symptom clusters (Gift et al., 2004) and another study used symptom distress in addition to severity to create the symptom clusters (Suwisith et al., 2008) .
While only one of these six studies identified seven symptom clusters (Hwang et al., 2016) , one identified a single symptom cluster (Gift et al., 2004) , one identified two symptom clusters (Wang et al., 2008) , one identified three symptom clusters (Wang & Fu, 2014) , and two identified four symptom clusters (Ryu et al., 2010; Suwisith et al., 2008) . Of note, a GI cluster was the only symptom cluster that was common among four of the studies (Ryu et al., 2010; Suwisith et al., 2008; Wang & Fu, 2014; Wang et al., 2008) . However, the symptoms within the GI cluster were not consistent across the four studies nor were the number of symptoms identified within this GI cluster consistent. In two of the studies (Wang & Fu, 2014; Wang et al., 2008) , nausea and vomiting were the only common symptoms in the GI symptom cluster T A B L E 1 (Continued) (Thomas et al., 2014) . The gender distribution of women was 45.9% (i.e., weighted grand mean). Ages ranged from 18-93 with a weighted grand mean of 58.9 years. All three of these studies recruited patients from outpatient settings.
Across these three studies, CTX was the most prevalent treatment modality used. Among the cancer diagnoses, lung (21.7%) and GI (23.3%) cancers were the most common in one study (Molassiotis et al., 2010) and GI (21.5%) and breast (28.8%) cancers in the other study (Skerman et al., 2012a) . In the third study (Thomas et al., 2014) , prostate (20.0%) and GI (26.2%) cancers were the most common diagnoses. Timing of the longitudinal symptom assessments occurred at peri-diagnosis and at three, six and 12 months in one study (Molassiotis et al., 2010) ; at time of diagnosis, three, six and 12 months in another study (Thomas et al., 2014) ; and at one, six and 12 months after the initiation of CTX in the other study (Skerman et al., 2012a) .
One study used the MSAS (32 items) to evaluate symptoms To create the symptom clusters, while one study did not specify the dimension used (Molassiotis et al., 2010) , symptom distress was used in one study (Skerman et al., 2012a) and symptom severity in the other study (Thomas et al., 2014) . In terms of the number of symptom clusters identified, one found three clusters (Thomas et al., 2014) , one found five clusters (Skerman et al., 2012a) , and one found six clusters (Molassiotis et al., 2010) . A GI cluster was common in two of the studies (Molassiotis et al., 2010; Skerman et al., 2012a) , and a nutrition cluster was common in two of the studies (Molassiotis et al., 2010; Thomas et al., 2014) . The number of symptoms identified within each symptom cluster was higher in the study with the five symptom clusters. In all three of these studies, the symptom clusters identified remained relatively consistent over time.
| Longitudinal studies of homogeneous samples
As shown in cancer diagnoses (Brown et al., 2011; Gift et al., 2003; Huang et al., 2016; Kim et al., 2008; Phligbua et al., 2013) . The sample sizes ranged from 111 (Huang et al., 2016 )-282 (Kim et al., 2008 . Across these studies, the majority of the patients were female (weighted grand mean of 92.8%). Ages ranged from 19 (Huang et al., 2016 )-89 (Brown et al., 2011 with a weighted grand mean of 59.0 years. All patients were recruited in outpatient settings. Radiation therapy was the primary treatment modality in two of the studies (Gift et al., 2003; Kim et al., 2008) , and one study evaluated patients whose primary treatment modality was surgery (Brown et al., 2011) . CTX was the primary treatment modality in two studies (Huang et al., 2016; Phligbua et al., 2013) . Two studies evaluated patients with lung cancer (Brown et al., 2011; Gift et al., 2003) , two evaluated women with breast cancer (Kim et al., 2008; Phligbua et al., 2013) , and one evaluated patients with ovarian cancer (Huang et al., 2016) . The timing of the symptom assessments ranged from two (i.e., the previous day and past four weeks in one study) (Brown et al., 2011)-four (i.e., before surgery, after first cycle, after third cycle, after sixth cycle CTX) (Huang et al., 2016) time points.
Nine different symptom assessment instruments were used to assess symptoms across these studies. One study used the Lung Cancer Symptom Scale (LCSS) (Brown et al., 2011) , and another study used the Physical Symptom Experience Tool (PSE) (Gift et al., 2003) . The third study used four instruments (i.e., General Fatigue Scale (GFS), Profile of Mood States-Short Form (PMS-SF), Pittsburgh Sleep Quality Index (PSQI), Side Effect Checklist (SEC)) (Kim et al., 2008) . The fourth study used the Chinese version of the MSAS (Huang et al., 2016) . The fifth study used a modified version of the MSAS with 39 symptoms (Phligbua et al., 2013) . The statistical methods used to identify the symptom clusters varied across the five studies. Four of the studies used factor analysis (Gift et al., 2003; Huang et al., 2016; Kim et al., 2008; Phligbua et al., 2013) , and one study (Brown et al., 2011) uniquely coded symptoms on the LCSS to analyse and to determine patterns of co-occurring symptoms.
Symptom occurrence (Brown et al., 2011; Gift et al., 2003) , symptom severity (Huang et al., 2016; Kim et al., 2008) and symptom distress (Phligbua et al., 2013) were the dimensions used to create the symptom clusters. Two studies identified one unnamed symptom cluster at the two (Brown et al., 2011) and three (Gift et al., 2003) time points that were assessed. A third study identified a psychoneurological and an upper GI symptom cluster at all three of the assessments (Kim et al., 2008) . In a fourth study that assessed for symptom clusters at four time points (Huang et al., 2016) , three symptom clusters were identified at Time 1 (T1), five symptom clusters at T2, six symptom clusters at T3 and six symptom clusters at T4. In the fifth study that assessed for symptom clusters at three time points (Phligbua et al., 2013) , five symptom clusters were identified at T1, five symptom clusters at T2 and five symptom clusters at T3. In two of the studies that evaluated patients with breast (Phligbua et al., 2013) and ovarian (Huang et al., 2016) cancer, the following symptom clusters were found in both studies: GI, psychological and menopausal.
In the two studies with an unnamed symptom cluster that both assessed patients with lung cancer (Brown et al., 2011; Gift et al., 2003) , fatigue and poor appetite were the two symptoms that were consistent within this symptom cluster in both studies. In terms of changes in symptom clusters over time, one study found that a single, unnamed symptom cluster remained stable over time (Gift et al., 2003) . In the studies that identified two to six symptom clusters across the time points assessed (Huang et al., 2016; Kim et al., 2008; Phligbua et al., 2013) , only one identified a psychoneurological symptom cluster that was present at all three time points (Kim et al., 2008) . In another study that found four to six symptom clusters across four time points (Huang et al., 2016) , the following three symptom clusters were relatively consistent over time: pain-related, psychological and menopausal. In the fifth study that identified five symptom clusters, at each of the three time points assessed (Phligbua et al., 2013) , the only symptom cluster that was consistent over time was labelled discomfort.
| DISCUSSION
In this review, various aspects of symptom cluster research were evaluated in studies that included, as part of their sample, oncology patients who received primary or adjuvant CTX. Of note, across the nineteen studies included in this review, only seven studies (36.8%) (Huang et al., 2016; Hwang et al., 2016; Phligbua et al., 2013; Skerman et al., 2012a; Suwisith et al., 2008; Wang & Fu, 2014; Yamagishi et al., 2009) included patients who received only CTX. The remaining studies included patients undergoing a variety of cancer treatments. Given this limitation, it is difficult to determine which symptom clusters are associated with a specific cancer treatment. In addition, because only 42.1% of the studies were longitudinal and included patients with both heterogeneous (Molassiotis et al., 2010; Skerman et al., 2012a; Thomas et al., 2014) and homogeneous (Brown et al., 2011; Gift et al., 2003; Huang et al., 2016; Kim et al., 2008; Phligbua et al., 2013) cancer diagnoses, definitive conclusions cannot be made about how symptom clusters change over time.
However, based on the prespecified objectives for this review, some interesting trends were identified.
| Symptom assessment instruments
The MDASI was used in 26.3% of the studies. The MDASI evaluates the severity of 13 common symptoms reported by oncology patients (i.e., pain, fatigue, nausea, sleep disturbance, distress, shortness of breath, problems remembering, lack of appetite, drowsiness, dry mouth, sadness, vomiting, numbness) (Cleeland et al., 2000) . However, the MDASI only evaluates the severity of these thirteen symptoms. The MSAS was used in 26.3% of the studies. The original version of the MSAS evaluates 32 symptoms commonly reported by oncology patients (Portenoy, Thaler, Kornblith, Lepore, Friedlanderklar, Coyle, et al., 1994; Portenoy, Thaler, Kornblith, Lepore, Friedlanderklar, Kiyasu, et al., 1994) . Of note, the MSAS evaluates multiple dimensions of the symptom experience (i.e., occurrence, frequency, severity, distress). Both instruments are valid and reliable and are widely used to investigate symptoms in oncology patients (Cleeland et al., 2000) (Portenoy, Thaler, Kornblith, Lepore, Friedlanderklar, Coyle, et al., 1994; Portenoy, Thaler, Kornblith, Lepore, Friedlanderklar, Kiyasu, et al., 1994) .
Of the five studies that used the MDASI (Chen & Lin, 2007; Chen & Tseng, 2006; Karabulut et al., 2010; Wang & Fu, 2014; Wang et al., 2008) , one study identified two symptom clusters (Wang et al., 2008) and four studies identified three symptom clusters (Chen & Lin, 2007; Chen & Tseng, 2006; Karabulut et al., 2010; Wang & Fu, 2014) . The only symptom cluster that was common across four of these studies was labelled a GI symptom cluster that included the symptoms of nausea and vomiting.
While all of the symptoms in the cluster were not completely identical, a "sickness behaviour" symptom cluster was identified in all five of the studies that used the MDASI (Chen & Lin, 2007; Chen & Tseng, 2006; Karabulut et al., 2010; Wang & Fu, 2014; Wang et al., 2008) . The identification of this sickness behaviour symptom cluster is consistent with a number of reviews that suggest that inflammatory responses associated with cancer and its treatment contribute to the development and severity of symptoms in oncology patients . Of note, an emotional symptom cluster, that included sadness, was identified in three of the studies that used the MDASI (Chen & Lin, 2007; Chen & Tseng, 2006; Wang & Fu, 2014) .
Of the five studies that used the MSAS (Huang et al., 2016; Molassiotis et al., 2010; Phligbua et al., 2013; Suwisith et al., 2008; Yates et al., 2015) , one study identified four symptom clusters (Suwisith et al., 2008) , another identified five clusters (Phligbua et al., 2013) , another identified six clusters (Molassiotis et al., 2010) , another identified seven clusters (Yates et al., 2015) and one identified from three-six clusters (Huang et al., 2016) . Across all five studies that used the MSAS, a GI symptom cluster was identified. In addition, in all five of these studies, an "emotional" or "mood-cognitive" cluster was identified. Finally, in four of the five studies (Huang et al., 2016; Molassiotis et al., 2010; Phligbua et al., 2013; Suwisith et al., 2008) , a body image symptom cluster was identified. It should be noted that the specific symptoms within the GI, emotional and body image clusters were not consistent across the five MSAS studies.
For both the MDASI (Chen & Lin, 2007; Chen & Tseng, 2006; Karabulut et al., 2010; Wang & Fu, 2014; Wang et al., 2008 ) and the MSAS (Huang et al., 2016; Molassiotis et al., 2010; Phligbua et al., 2013; Suwisith et al., 2008; Yates et al., 2015) studies, the inconsistencies in the number and types of symptom clusters identified as well as the specific symptoms within each cluster may be related to variations in cancer diagnoses and treatments, as well as the timing of the symptom assessments within the context of cancer treatment. For the MSAS studies, the dimension of the symptom experience that was used to create the symptom clusters (i.e., occurrence, severity, distress) may have contributed to the variability in the number and types of symptom clusters identified.
However, the consistent findings across the studies that used the MDASI or the MSAS suggest that substantial progress could be made in symptom cluster research if investigators used a single (e.g., MDASI) or multidimensional (e.g., MSAS) symptom assessment instrument on a more consistent basis. Of note, the identification of a GI symptom cluster and a psychological symptom cluster using both the MDASI and the MSAS suggests that these two symptom clusters warrant additional investigation.
| Statistical approaches
While a debate exists on the most appropriate statistical approach to use to identify symptom clusters (Skerman, Yates, & Battistutta, 2012b; Skerman et al., 2009) , 72.7% of the cross-sectional studies and 87.5% of the longitudinal studies used some type of factor analysis to create the symptom clusters. However, the specific type of factor analysis (i.e., EFA, CFA) varied across these studies.
A growing body of literature , Miaskowski et al., 2017 Skerman et al., 2012b) suggests that factor analysis may be the best analytical method to create symptom clusters.
One reason for using factor analysis is that this analytical method assesses all data and any missing data do not influence the extraction of specific factors (Skerman et al., 2012b) . Additionally, using factor analysis to extract symptom clusters allows for individual symptoms to load on more than one factor. While in test construction, a single item cannot load on more than one factor; it is possible that a single symptom may load on multiple factors (i.e., multiple symptom clusters). This hypothesis is supported by the fact that in several studies included in this review (Chen & Tseng, 2006; Karabulut et al., 2010; Wang et al., 2008) , pain and fatigue loaded on more than one factor (i.e., symptom cluster).
According to Skerman et al. (2012b) , once the factor analysis is completed, clinicians need to determine whether the symptoms that load on a particular factor make sense as a "symptom cluster." They suggested that one reason a symptom may load on more than one symptom cluster is that this symptom contributes to the causal mechanisms underlying each specific symptom cluster. Additional research is warranted to determine the most common symptoms that load on multiple symptom clusters. This level of analysis may provide insights into which symptom clusters share common versus unique underlying mechanisms.
| Symptom dimensions
Seventeen of the 19 studies reported the symptom dimension that was used to create the symptom cluster. Across these 17 studies, 47.1% used symptom severity (Chen & Lin, 2007; Chen & Tseng, 2006; Huang et al., 2016; Kim et al., 2008; Ryu et al., 2010; Thomas et al., 2014; Wang & Fu, 2014; Wang et al., 2008) , 17.6% used symptom occurrence (Brown et al., 2011; Gift et al., 2003; Yates et al., 2015) , 11.8% used symptom distress (Phligbua et al., 2013; Skerman et al., 2012a) , and 5.9% used either severity and interfer- 2004), or severity and distress (Suwisith et al., 2008) to create the symptom clusters. Of the nine studies that used the severity dimension of the symptom experience to create the symptom clusters, one used the MSAS (Huang et al., 2016) , three used the MDASI (Chen & Lin, 2007; Chen & Tseng, 2006; Wang et al., 2008) , and five used a combination of instruments (Brown et al., 2014; Kim et al., 2008; Ryu et al., 2010; Thomas et al., 2014; Wang & Fu, 2014) to create the symptom clusters.
Only one study of the nineteen included in this review evaluated for differences in symptom clusters based on the dimension of the symptom evaluated (Suwisith et al., 2008) . In this study, four symptom clusters (i.e., emotions-related, GI and fatigue-related, imagerelated/cutaneous, pain-related discomfort) were identified using severity ratings. Using distress ratings, three symptom clusters were identified (i.e., emotions and pain-related discomfort, GI symptoms, image-related/cutaneous).
Given the extreme variability in the dimensions used to create the symptom clusters, additional research is warranted that compares the number and types of symptom clusters that are created when occurrence, severity, frequency and/or distress are used in the same set of analyses. This evaluation needs to be done using a valid and reliable instrument like the MSAS and in samples of patients who are relatively homogenous in terms of their cancer diagnoses, cancer treatments and/or stage of disease (e.g., curative, palliative, survivor).
| Number and types of symptom clusters
Across the 19 studies, the number of symptom clusters identified ranged from one-seven. Both cluster analysis and factor analysis approaches yielded approximately the same number of symptom clusters. However, the number and specific symptoms within each symptom cluster were highly variable.
The "GI" symptom cluster (Chen & Lin, 2007; Chen & Tseng, 2006; Huang et al., 2016; Kim et al., 2008; Molassiotis et al., 2010; Phligbua et al., 2013; Ryu et al., 2010; Skerman et al., 2012a; Suwisith et al., 2008; Wang & Fu, 2014; Wang et al., 2008; Yates et al., 2015) or an unnamed symptom cluster that contained GI symptoms (Karabulut et al., 2010; Yamagishi et al., 2009 ) was the most common symptom cluster identified in thirteen of the nineteen studies included in this review. However, the specific symptoms and number of symptoms found within the GI symptom cluster varied considerably. Across these thirteen studies, the symptoms of nausea and vomiting were found in ten of the studies that identified a GI symptom cluster.
The second most common symptom cluster identified was a "psychological" symptom cluster. While this symptom cluster was identified in twelve studies (Chen & Lin, 2007; Chen & Tseng, 2006; Huang et al., 2016; Hwang et al., 2016; Kim et al., 2008; Molassiotis et al., 2010; Phligbua et al., 2013; Suwisith et al., 2008; Thomas et al., 2014; Wang & Fu, 2014; Yamagishi et al., 2009; Yates et al., 2015) , it had a variety of labels, including emotional symptoms, mood/cognitive, psychological distress, psychological and psychoneurological. Across these twelve studies, the common symptoms in the "psychological" symptom cluster were as follows: feeling sad, worry, depression and anxiety.
The third most common symptom cluster identified was a "sickness behaviour" symptom cluster. This symptom cluster was named "sickness symptoms" in two studies by the same researchers (Chen & Lin, 2007; Chen & Tseng, 2006) , was named "general symptoms" in another study (Wang et al., 2008) , was referred to as "malaise" in another study (Yates et al., 2015) , was labelled fatigue-related in another study and was unnamed in another study (Karabulut et al., 2010) . Across these five studies, the common symptoms in the "sickness behaviour" symptom cluster were as follows: pain, fatigue, disturbed sleep, drowsiness and lack of appetite.
T A B L E 5 Questions that may be useful to guide future cancer symptom clusters research
Assessment of symptom clusters
What is the optimal number of symptoms on an assessment tool to evaluate symptoms clusters?
Does the optimal symptom cluster assessment need to include both a core set of symptoms and "situation-specific" symptoms (e.g., tailored symptom list for specific cancers or specific treatments)?
What is the optimal dimension of the symptom experience to use to assess symptom clusters (i.e., occurrence, severity, distress)?
Should multiple dimensions of the symptom experience be used to assess symptom clusters?
Specificity of symptom clusters by patient characteristics, cancer diagnosis and treatments Across cancer diagnoses, are symptom clusters consistent in terms of number of clusters and symptoms within each cluster?
Across cancer treatments are symptom clusters consistent in terms of number of clusters and symptoms within each cluster?
Do symptom clusters in patients with cancer or in patients undergoing cancer treatment differ by age, gender or ethnicity?
Do symptom clusters in patients with cancer or in patients undergoing cancer treatment differ by comorbidities, functional status, or social status?
Changes in symptom clusters over time Within a cancer diagnosis, do symptom clusters change over time?
Within a cancer treatment modality, do symptom clusters change over time?
Within a cancer diagnosis, does the severity of the symptoms within a symptom cluster change over time?
Within a cancer treatment modality, does the severity of the symptoms within a symptom cluster change over time?
The variability in the number and types of symptom clusters may relate to the diversity of the patients included in these studies based on their cancer diagnoses and types of treatments; the diversity in the symptom assessment instruments used, as well as in the methods used to create the symptom clusters. Of note, across these nineteen studies, neither the use of instruments with a larger number of items nor the use of multiple instruments to evaluate symptom clusters yielded a larger number of symptom clusters.
| Changes in symptom clusters over time
Of the nineteen studies evaluated in this review, 42.1% were longitudinal (Brown et al., 2011; Gift et al., 2003; Huang et al., 2016; Kim et al., 2008; Molassiotis et al., 2010; Phligbua et al., 2013; Skerman et al., 2012a; Thomas et al., 2014) . The timing of the assessments ranged from the previous day to the past 4 weeks (two assessments) (Brown et al., 2011) , to around the time of diagnosis to a maximum of 12 months after diagnosis (i.e., four time points) (Huang et al., 2016; Molassiotis et al., 2010; Thomas et al., 2014) .
Across these eight longitudinal studies, only 37.5% found that the symptom clusters were relatively stable over time (Gift et al., 2003; Molassiotis et al., 2010; Thomas et al., 2014) .
| Limitations of this review of the literature
While a comprehensive review of the literature was done, some studies may have been missed due to the various search terms used for cancer symptom clusters research. In addition, the timing of the last search of the literature for cancer symptom clusters may have not captured the final studies published in 2016. Of note, the findings from this review may not generalise to paediatric oncology patients and to oncology patients who are receiving palliative or hospice care.
| Areas for future research
To date, many questions about symptom clusters research in oncology patients remain unanswered. These research questions, which are organised, based on the themes and findings from this review are summarised in Table 5 . Answering these questions will advance our understanding of symptom clusters, as well as the role that symptom clusters play in the symptom experience of oncology patients receiving CTX. In addition, information on common symptom clusters may lead to the development and the testing of novel symptom management interventions for oncology patients. Given that findings from initial studies suggest that symptom clusters occur in patients with other chronic medical conditions (Amro, Waldum, Dammen, Miaskowski, & Os, 2014; Amro et al., 2016; Burgel et al., 2010; Song, Moser, Rayens, & Lennie, 2010) , the questions raised in this review warrant consideration in future studies. An important area for research is whether common symptom clusters exist across chronic conditions and which symptom clusters are unique to chronic conditions such as diabetes, heart failure, chronic renal disease and chronic obstructive pulmonary disease.
